Prognostic Value of Hyperglycemia on Admission on In-hospital Outcomes in Patients Presenting with ST-elevation Myocardial Infarction

Muhammad Shahid 1, Hafiz Muhammad Asif Zarif 1, Muhammad Shahzad Farid 1, Muhammad Shoaib Abid 1, Burhan Akhtar 1, Momin Rasheed Khan 1

1. Cardiology, Ch. Pervaiz Elahi Institute of Cardiology, Multan, PAK

Corresponding author: Muhammad Shahid, doc.cpeic@gmail.com

Abstract

Background

Type 2 diabetes mellitus (T2DM) is associated with acute coronary syndrome, and elevated blood glucose levels on hospital admission may influence outcomes in patients with ST-elevated myocardial infarction (STEMI). We conducted this study to determine the prognostic outcome of hyperglycemia at admission on in-hospital outcomes of STEMI patients with and without T2DM.

Methods

This prospective study was conducted from June 13, 2018, to October 12, 2019, and included patients older than 18 years diagnosed with STEMI. For our purposes, hyperglycemia was defined as blood glucose levels >140 mg/dl. Hypertension was considered as systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg. The predictive value of glycemia on admission for outcomes was assessed via patient mortality following thrombolysis or percutaneous coronary intervention (PCI).

Results

Our study included 256 patients (196 men, 76.5%; 60 women, 23.5%) with a mean age of 55 ± 11 years. A total of 92 patients (35.9%) were admitted with known T2DM diagnoses: 72 of them had hyperglycemia and 20 patients had euglycemia (p = 0.0001). Post-PCI mortality was six (18.8%) in the hyperglycemic group and one (2.2%) in the euglycemic group (p = 0.03). In-hospital mortality was higher in the hyperglycemic group (n = 12, 12.5%) compared to the euglycemic group (n = 6, 3.7%; p = 0.015). Significant risk factors of mortality for STEMI patients with hyperglycemia on admission were age 60 years or older (odds ratio [OR], 5.63 [1.54-20.58]; p = 0.007), heart failure on admission (OR, 6.84 [1.85-25.22]; p = 0.003), T2DM (OR, 4.14 [0.50-33.96]; p = 0.05), and presenting with renal failure (OR, 6.78 [1.74-26.42]; p = 0.009).

Conclusion

Thrombolysis and PCI are effective and safe treatments in STEMI patients. Hyperglycemia has a great adverse impact on hospital outcomes in patients with or without T2DM. STEMI patients with hyperglycemia on hospital admission have higher mortality rates.
Introduction

Type 2 diabetes mellitus (T2DM) is a major health problem globally. According to the World Health Organization, the prevalence of diabetes in adults has increased from 4.7% in 1980 to 8.5% in 2014 [1]. The prevalence has been increasing rapidly in developing countries like Pakistan [2]. There is a strong correlation between T2DM and acute coronary syndrome (ACS), and the prevalence rate of ACS in T2DM patients has increased from 18% in 1997 to 22.6% in 2018 [5]. The prevalence of T2DM is higher in women (26.3%) than in men (20.8%) [4]. T2DM patients with ACS have high chances of atherosclerosis, myocardial infarction, and worse outcomes compared to patients without T2DM. Patients diagnosed with ST-elevated myocardial infarction (STEMI) with hyperglycemia on hospital admission represent a greater clinical challenge in achieving outcomes normally expected following thrombolysis or percutaneous coronary intervention (PCI) [5,6].

The pathophysiological mechanisms of thrombus formation, vascular inflammation, and platelet aggregation are different in T2DM patients compared to patients without T2DM [7,8]. ACS patients with STEMI but without T2DM have higher chances of successful treatment than those with T2DM. However, the possible link between diabetes, hyperglycemia, and STEMI and early outcomes has not yet been established. We conducted this study to determine the prognostic outcome of hyperglycemia at the time of hospital admission in STEMI patients with and without T2DM.

Materials And Methods

We conducted this prospective study on STEMI patients admitted in the emergency department of Ch. Pervaiz Elahi Institute of Cardiology from June 13, 2018, to October 12, 2019. The study included patients older than age 18 years diagnosed as STEMI. The diagnostic criteria for STEMI were chest discomfort and angina lasting longer than 30 minutes, ST-elevation >0.1 mV in two adjacent electrocardiography leads, and at least one elevated biomarker (creatine kinase myocardial band, creatine phosphokinase, or troponin I).

All patients received a blood glucose test on admission. Hyperglycemia was defined as blood glucose levels >140 mg/dl. All patients underwent a routine laboratory test to identify T2DM. Hypertension was defined as systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg. Acute renal failure was defined as using progressive increase in serum creatinine ≥ 0.3 mg/dl over 48 hours.

Our study was approved by the institutional ethical research body. Patient information was kept confidential, and no identifying data were disclosed. Initially, 289 patients were evaluated, but 33 were excluded from the study population due to a lack of blood glucose values on admission. The study population consisted of 256 patients. Patients were sorted into two groups based on glucose levels on admission: a hyperglycemia group (with blood glucose >140 mg/dl) and a euglycemic group (with blood glucose <140 mg/dl). Outcomes were assessed via the mortality rate following treatment with thrombolysis or PCI.

Study data were analyzed using IBM SPSS Statistics for Windows, Version 23.0 (Armonk, NY: IBM Corp.), and quantitative variables were calculated as mean ± standard deviation. Categorical variables were calculated as frequency and percentage. To compare the groups, we used the χ2 test and unpaired sample t-tests. P-values <0.05 were considered statistically significant.
Results

Patient demographics and baseline clinical information is presented in Table 1. Our study included 256 patients (196 men, 76.5%; 60 women, 23.5%) with a mean age of 55 ± 11 years. The hyperglycemia group contained 96 patients (75 men, 78.13%; 21 women, 21.87%) and the euglycemic group contained 160 patients (121 men, 75.63%; 39 women, 24.37%; p = 0.03). Eighty-six patients (29.7%) had hypertension. A total of 92 patients had known T2DM on admission: 72 patients were in the hyperglycemic group and 20 were in the euglycemic group (p = 0.0001). The mean duration of T2DM in the study population was 6.2 ± 3.8 years. Heart failure on admission was more prevalent in the hyperglycemic group (28.12%) as compared to the euglycemic group (18.75%; p = 0.11), indicating an association of hyperglycemia with heart failure.

| Characteristic                  | Population (N = 256) | Hyperglycemia group (n = 96) | Euglycemia group (n = 160) | P-value |
|--------------------------------|----------------------|-----------------------------|---------------------------|---------|
| Age ± SD (years)               | 55 ± 11              | 55 ± 10                     | 54 ± 12                   | 0.30    |
| Gender ratio, male (%) / female (%) | 196 (76.5%)/ 60 (23.5%) | 75 (78.13%)/ 21 (21.87%) | 121 (75.63%)/ 39 (24.37%) | 0.03/0.76 |
| Hypertension (%)               | 86 (29.7%)           | 36 (37.5%)                  | 50 (31.25%)               | 0.37    |
| Diabetes (%)                   | 92 (35.93%)          | 72 (75%)                    | 20 (12.5%)                | 0.0001  |
| Smoker (%)                     | 168 (65.6%)          | 54 (56.25%)                 | 104 (65.0%)               | 0.20    |
| History of CAD (%)             | 30 (11.7%)           | 12 (12.5%)                  | 18 (11.25%)               | 0.92    |
| Heart failure on admission (%) | 57 (22.26%)          | 27 (28.12%)                 | 30 (18.75%)               | 0.11    |
| Cardiogenic shock (%)          | 5 (1.9%)             | 2 (2.08%)                   | 3 (1.8%)                  | 0.72    |
| Acute renal failure (%)        | 24 (9.3%)            | 13 (13.54%)                 | 11 (6.8%)                 | 0.11    |

TABLE 1: Demographic and baseline clinical data

CAD, coronary artery disease; SD, standard deviation.

Patients were treated with thrombolysis or primary PCI. Thrombolytic treatment was given to 27 patients in the hyperglycemia group (28.1%) and 75 patients in the euglycemic group (46.8%; p = 0.004). Primary PCI was performed in 33 patients in the hyperglycemia group (54.3%) and 45 patients in the euglycemic group (28.12%; p = 0.36). Post-PCI mortality was six (18.8%) in the hyperglycemic group and one (2.2%) in the euglycemic group (p = 0.03). Overall in-hospital mortality was higher in the hyperglycemic group (n = 12, 12.5%) than in the euglycemic group (n = 6, 3.7%; p = 0.015; Table 2).
Univariate analysis revealed that significant risk factors of mortality in patients with hyperglycemia on admission were age 60 years or older (odds ratio [OR], 5.63 [1.54-20.58]; p = 0.007), heart failure on admission (OR, 6.84 [1.85-25.22]; p = 0.003), T2DM (OR, 4.14 [0.50-33.96]; p = 0.05), and presenting with renal failure (OR, 6.78 [1.74-26.42]; p = 0.009; Table 3).
Predictor | Odds ratio (95% CI) | P-value
---|---|---
Female gender | 0.37 (0.10-1.35) | 0.15
Age ≥60 years | 5.63 (1.54-20.58) | 0.007
Hypertension | 0.81 (0.22-2.91) | 0.50
Diabetes mellitus | 4.14 (0.50-33.96) | 0.05
Smoking | 0.51 (0.15-1.74) | 0.35
Heart failure on admission | 6.84 (1.85-25.22) | 0.003
Cardiogenic shock | 7.54 (0.43-129.4) | 0.23
Renal failure | 6.78 (1.74-26.42) | 0.009

TABLE 3: Univariate analysis of predictors of in-hospital mortality in patients with hyperglycemia at admission
CI, confidence interval.

Discussion

In 2013, the European Society of Cardiology and the European Association for the Study of Diabetes issued guidelines for glycemic control in patients with cardiac disease with major goals to improve management in STEMI patients [9]. In the present study, we provide an estimation of the burden of STEMI patients with hyperglycemia and the associated risks for in-hospital mortality. Hyperglycemia with STEMI is a powerful predictor of poor in-hospital outcomes [10]. We found that STEMI patients with hyperglycemia develop more complications such as heart failure, cardiogenic shock, and atherosclerosis compared to euglycemic STEMI patients. While modern anti-hyperglycemic agents are effective in the treatment of elevated blood glucose levels, these drugs also affect the cardiovascular system [11-13].

In our study, hyperglycemic STEMI patients at the time of hospital admission had a higher mortality rate than euglycemic STEMI patients, even after reperfusion. Hyperglycemia’s impact on in-hospital outcomes does not seem to depend on the reperfusion strategy. According to Planer et al., hyperglycemia caused cardiac crises of myocardial re-infarct and bleeding following PCI [14]. Malmberg et al. reported that in STEMI patients stabilized by thrombolysis, hyperglycemia was associated with a higher mortality rate compared with euglycemic patients [5]. A Japanese study reported that hyperglycemia in patients with STEMI was associated with higher morbidity of large infarcts and higher in-hospital mortality compared with euglycemic patients [15]. STEMI outcomes in patients with T2DM can be improved after controlling blood glucose levels [16].

The significant risk factors of in-hospital mortality in hyperglycemia patients, according to our findings, were patient age of ≥60 years, T2DM, heart failure, and renal failure. Jomaa et al. reported similar risk factors such as age ≥75 years, anemia, heart failure, cardiogenic shock, renal failure, and bleeding as independent predictors of mortality in T2DM patients presenting with hyperglycemia [17].
Limitation of the study

Our study was limited in that the sample size was small. Future similar studies should be conducted in a large center with a larger study population to confirm cardiac outcomes of STEMI patients with hyperglycemia at admission.

Conclusions

Hyperglycemia is independently associated with cardiac death in STEMI patients, and the predictive value of hyperglycemia is higher in T2DM patients compared to patients without T2DM. Hyperglycemia with STEMI has been a challenge for cardiologists around the world, and better management with effective treatment is the only strategy to decrease the morbidity and mortality rate.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. Department of Academic Affairs, CPEIC Multan issued approval CPEIC-042-2019. The ethical approval for this study was taken from department of academic affairs and ethical review board of Ch. Pervaiz Elahi Institute of Cardiology (IRB Number; CPEIC-042-2019). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. World Health Organization. Diabetes fact sheet. (2018). Accessed: February 10, 2020: https://www.who.int/news-room/fact-sheets/detail/diabetes.
2. Aamir AH, Ul-Haq Z, Mahar SA, et al.: Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan. BMJ Open. 2019, 9:e025300. 10.1136/bmjopen-2018-025300
3. Jiang SL, Ji XP, Zhao YX, et al.: Predictors of in-hospital mortality difference between male and female patients with acute myocardial infarction. Am J Cardiol. 2006, 98:1000-1003. 10.1016/j.amjcard.2006.05.015
4. Liu J, Zhao D, Liu Q, et al.: Study on the prevalence of diabetes mellitus among acute coronary syndrome inpatients in a multiprovincial study in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2008, 29:526-529.
5. Malmberg K, Norhammar A, Wedel H, Rydén L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999, 99:2626-2632. 10.1161/01.cir.99.20.2626
6. Timmer JR, Hoekstra M, Nijsten MW, et al.: Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. Circulation. 2011, 124:704-711. 10.1161/CIRCULATIONAHA.110.985911
7. Colwell JA, Nesto RW: The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003, 26:2181-2188. 10.2337/diacare.26.7.2181
8. Ferroni P, Basilis S, Falco A, Davi G: Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004, 2:1282-1291. 10.1111/j.1538-7836.2004.00836.x
9. Authors/Task Force Members, Rydén L, Grant PJ, et al.: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013, 34:3035-3087. 10.1093/eurheartj/eht108

10. Kim EJ, Jeong MH, Kim JH, et al.: Clinical impact of admission hyperglycemia on in-hospital mortality in acute myocardial infarction patients. Int J Cardiol. 2017, 256:9-15. 10.1016/j.ijcard.2017.01.095

11. Wang MT, Lin SC, Tang PL, et al.: The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction. Cardiovasc Diabetol. 2017, 16:89. 10.1186/s12933-017-0572-0

12. Zinman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-2128. 10.1056/NEJMoa1504720

13. Chan CW, Yu CL, Lin JC, et al.: Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. Cardiovasc Diabetol. 2018, 17:20. 10.1186/s12933-018-0663-6

14. Planer D, Witzenbichler B, Guagliumi G, et al.: Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol. 2015, 167:2572-2579. 10.1016/j.ijcard.2012.06.054

15. Fujino M, Ishihara M, Honda S, et al.: Impact of acute and chronic hyperglycemia on inhospital outcomes of patients with acute myocardial infarction. Am J Cardiol. 2014, 114:1789-1795. 10.1016/j.amjcard.2014.09.015

16. Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y: Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006-2013). Cardiovasc Diabetol. 2017, 16:1. 10.1186/s12933-016-0482-6

17. Jomaa W, El Mhamdi S, Ben Ali I, et al.: Prognostic value of hyperglycemia on-admission in diabetic versus non-diabetic patients presenting with ST-elevation myocardial infarction in Tunisia. Indian Heart J. 2018, 70:772-776. 10.1016/j.ihj.2018.01.005